{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:45:36Z","timestamp":1773096336801,"version":"3.50.1"},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants.<\/jats:p><jats:p>We analyzed VLBW infants with ROP (stages 2\u20133, zones II-III). Newborns received oral propranolol (0.5 mg\/kg\/dose q8h), and were monitored throughout the treatment period for possible side effects. Propranolol was administered until regression of ROP. A historic control group of patients with equivalent ROP was used. We compared characteristics of both groups and the progression of retinopathy.<\/jats:p><jats:p>Forty-seven newborns were included, 20 in the propranolol group and 27 in the control group. There were no significant differences in gestational age, birthweight or gender. The mean duration of treatment with propranolol was 58.2\u00b117.6 days. Most patients started treatment with stage 2 disease (65.0%), and had zone III involvement (55.0%). In the treated group, 90.0% (18\/20) of patients did not require intervention with laser or bevacizumab, compared to 51.8% in the control group (P&lt;0.005). No cases of bradycardia, hypotension or hypoglycemia were observed.<\/jats:p><jats:p>Oral propranolol in early stages of ROP could prevent disease progression and reduce the need for invasive rescue therapy with laser or bevacizumab. No significant side effects were reported.<\/jats:p>","DOI":"10.1515\/jpm-2015-0357","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T10:35:46Z","timestamp":1454582146000},"source":"Crossref","is-referenced-by-count":32,"title":["Oral propranolol in early stages of retinopathy of prematurity"],"prefix":"10.1515","volume":"44","author":[{"given":"Aldo","family":"Bancalari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Schade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Lazcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Parada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref101","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1542\/peds.2007-0803","article-title":"Infantile hemangiomas and retinopathy of prematurity: posible association","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0095-5108(18)30030-7","article-title":"Blood pressure measurements in the newborn","volume":"26","year":"1999","journal-title":"Clin Perinatol."},{"key":"ref11","first-page":"114","article-title":"Retinopathy of prematurity: incidence and associated factors","volume":"71","year":"2000","journal-title":"Rev Chil Pediatr."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/aos.12049","article-title":"The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge","volume":"92","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref181","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","article-title":"Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells","volume":"53","year":"2010","journal-title":"Vascul Pharmacol."},{"key":"ref351","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/archderm.1956.01550060038007","article-title":"Skin hemangioma and retrolental fibroplasia","volume":"73","year":"1956","journal-title":"AMA Arch Derm."},{"key":"ref41","first-page":"376","article-title":"Attenuation of choroidal neovascularization by \u03b2(2)-adrenoreceptor antagonism","volume":"13","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref271","first-page":"114","article-title":"Retinopathy of prematurity: incidence and associated factors","volume":"71","year":"2000","journal-title":"Rev Chil Pediatr."},{"key":"ref291","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade","volume":"52","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref421","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","year":"2015","journal-title":"N Engl J Med."},{"key":"ref171","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1525-1470.2009.00975.x","article-title":"Propranolol treatment for hemangioma of infancy: risks and recommendations","volume":"26","year":"2009","journal-title":"Pediatr Dermatol."},{"key":"ref461","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","article-title":"Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study","volume":"98","year":"2013","journal-title":"Arch Dis Child."},{"key":"ref511","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/pr.2014.108","article-title":"Pharmacokinetics and local safety profile of propranolol eye drops in rabbits","volume":"76","year":"2014","journal-title":"Pediatr Res."},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archophthalmol.2010.234","article-title":"Natural history of retinopathy of prematurity in infants born before 27 weeks gestation in Sweden","volume":"128","year":"2010","journal-title":"Arch Ophthalmol."},{"key":"ref81","first-page":"59","article-title":"Protective effects of \u03b21\/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy","volume":"56","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref251","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/pr.2014.108","article-title":"Pharmacokinetics and local safety profile of propranolol eye drops in rabbits","volume":"76","year":"2014","journal-title":"Pediatr Res."},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"ref161","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","year":"2015","journal-title":"N Engl J Med."},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"ref401","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000381659","article-title":"Oral propranolol: a new treatment for infants with retinopathy of prematurity?","volume":"108","year":"2015","journal-title":"Neonatology"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","article-title":"Antiangiogenic effects of \u03b22-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy","volume":"119","year":"2011","journal-title":"J Neurochem."},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/aos.12049","article-title":"The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge","volume":"92","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref441","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","article-title":"Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells","volume":"53","year":"2010","journal-title":"Vascul Pharmacol."},{"key":"ref61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","year":"2013","journal-title":"Semin Cancer Biol."},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archophthalmol.2010.234","article-title":"Natural history of retinopathy of prematurity in infants born before 27 weeks gestation in Sweden","volume":"128","year":"2010","journal-title":"Arch Ophthalmol."},{"key":"ref301","first-page":"376","article-title":"Attenuation of choroidal neovascularization by \u03b2(2)-adrenoreceptor antagonism","volume":"13","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/adc.2010.208884","article-title":"Propranolol for infantile haemangiomas: a review","volume":"96","year":"2011","journal-title":"Arch Dis Child."},{"key":"ref201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","article-title":"Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study","volume":"98","year":"2013","journal-title":"Arch Dis Child."},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","article-title":"Antiangiogenic effects of \u03b22-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy","volume":"119","year":"2011","journal-title":"J Neurochem."},{"key":"ref391","first-page":"103","article-title":"The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases","volume":"42C","year":"2014","journal-title":"Prog Retin Eye Res."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade","volume":"52","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref431","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1525-1470.2009.00975.x","article-title":"Propranolol treatment for hemangioma of infancy: risks and recommendations","volume":"26","year":"2009","journal-title":"Pediatr Dermatol."},{"key":"ref321","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","year":"2013","journal-title":"Semin Cancer Biol."},{"key":"ref361","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1542\/peds.2007-0803","article-title":"Infantile hemangiomas and retinopathy of prematurity: posible association","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref111","first-page":"160","article-title":"Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients","volume":"112","year":"2014","journal-title":"Arch Argent Pediatr."},{"key":"ref501","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IAE.0000000000000270","article-title":"Natural history of retinopathy of prematurity: two-year outcomes of a prospective study","volume":"35","year":"2015","journal-title":"Retina"},{"key":"ref131","first-page":"103","article-title":"The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases","volume":"42C","year":"2014","journal-title":"Prog Retin Eye Res."},{"key":"ref141","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000381659","article-title":"Oral propranolol: a new treatment for infants with retinopathy of prematurity?","volume":"108","year":"2015","journal-title":"Neonatology"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/adc.2010.208884","article-title":"Propranolol for infantile haemangiomas: a review","volume":"96","year":"2011","journal-title":"Arch Dis Child."},{"key":"ref371","first-page":"160","article-title":"Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients","volume":"112","year":"2014","journal-title":"Arch Argent Pediatr."},{"key":"ref341","first-page":"59","article-title":"Protective effects of \u03b21\/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy","volume":"56","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref91","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/archderm.1956.01550060038007","article-title":"Skin hemangioma and retrolental fibroplasia","volume":"73","year":"1956","journal-title":"AMA Arch Derm."},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives","volume":"163","year":"2013","journal-title":"J Pediatr."},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives","volume":"163","year":"2013","journal-title":"J Pediatr."},{"key":"ref71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1476-5381.2010.01078.x","article-title":"Impaired neoangiogenesis in \u03b22-adrenoceptor gene-deficient mice: restoration by intravascular human \u03b22-adrenoceptor gene transfer and role of NFkB and CREB transcription factors","volume":"162","year":"2011","journal-title":"Br J Pharmacol."},{"key":"ref221","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0095-5108(18)30030-7","article-title":"Blood pressure measurements in the newborn","volume":"26","year":"1999","journal-title":"Clin Perinatol."},{"key":"ref01","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000322848","article-title":"A paradigm shift in the prevention of retinopathy of prematurity","volume":"100","year":"2011","journal-title":"Neonatology"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IAE.0000000000000270","article-title":"Natural history of retinopathy of prematurity: two-year outcomes of a prospective study","volume":"35","year":"2015","journal-title":"Retina"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1476-5381.2010.01078.x","article-title":"Impaired neoangiogenesis in \u03b22-adrenoceptor gene-deficient mice: restoration by intravascular human \u03b22-adrenoceptor gene transfer and role of NFkB and CREB transcription factors","volume":"162","year":"2011","journal-title":"Br J Pharmacol."},{"key":"ref261","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000322848","article-title":"A paradigm shift in the prevention of retinopathy of prematurity","volume":"100","year":"2011","journal-title":"Neonatology"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2015-0357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:32:54Z","timestamp":1619055174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2015-0357\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":50,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1515\/jpm-2015-0357","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}